-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Either way, the survival model is designed to keep the business alive in such difficult tim.
Recently, several pharmaceutical companies have made new mov.
Based on recent developments in pharmaceutical companies, we summarize the survival models of four biotech compani.
Mode one
Mode oneTreat government contracts (BARDA) as a way to make a living
Treat government contracts (BARDA) as a way to make a livingBARDA's full name is the Biomedical Advanced Research and Development Authority, a division of the.
BARDA's full name is the Biomedical Advanced Research and Development Authority, a division of the.
Recently, Emergent entered into an agreement with Chimerix for exclusive rights to Tembexa, a smallpox treatment option for all ages approved in 2021, for a one-time upfront payment of $225 million in cash upon closing, and Phased payments totaling $100 milli.
Chimerix Chief Executive Mike Sherman said the company will forgo its investment in another program because regulators cannot expedite approval and will fully support Tembexa, the leading dr.
The deal for Tembexa, a small molecule drug, expands the company's work in the government's smallpox prevention strategy, said Paul Williams, Emergent's senior vice president of government affai.
The transaction will be completed within the next 3 to 6 months and is expected to be awarded the US Biomedical Advanced Research and Development Authority (BARDA) contra.
The active pharmaceutical ingredient of Tembexa (brincidofovir) is brincidofovir, a nucleotide anal.
When the.
When the.
Leverage our long and successful history of working with the.
How does Emergent make a living off government contracts?
Just when Emergent was in need of some breakthroughs, a ride on Tembexa was a victory for Emerge.
Riding a ride with Tembexa is a victory for Emerge.
Emergent signed an anthrax vaccine deal with the United States on September 11, 2001, and has since made government contracts its bread and butt.
In 2020, Emergent won a $628 million contract from the Donald Trump administration to produce a Covid-19 vaccine without a competing bid, culminating in the Baltimore accide.
At the time, a report from the.
House of Representatives Select Committee on the Coronavirus Crisis said the number of Covid-19 vaccines was closer to 400 million doses, compared with a much smaller number initially reported, due to cross-contamination issues at the Baltimore pla.
The report also said Emergent executives sought to cover up the problem, ignoring a report from a quality-control executive who said the site was unsuitable for the task it was about to underta.
Emergent has vehemently denied the report's findin.
Chloroquine and hydroxychloroquine, which Trump has repeatedly touted, can be used to treat the new crown pneumonia incident, which has made the BARDA agency a fi.
He was removed from his post as BARDA director after then-BARDA director Rick Bright refused to use hydroxychloroquine and chloroquine as treatments for COVID-1
Mode two
Mode twoCancel cooperation and cut off product lines with poor test data
Cancel cooperation and cut off product lines with poor test data Under the bear market, in addition to the problem of financial constraints, major pharmaceutical companies have to bear the consequences of poor test da.
Not every pharmaceutical company can bear the cost of failing trials and starting all over aga.
Even a big pharmaceutical company like Otsuka has to cancel the multi-billion-dollar CKD license agreement and cut off the product line with poor prospects due to poor trial data and the FDA issuing CRL due to safety concer.
Otsuka cancels CKD licensing agreement with Akebia
Back in 2016, Otsuka and Akebia signed the first license and co-development agreement for vadadustat, a drug candidate for the treatment of renal anemia associated with chronic kidney disea.
In 2017, the two biotech companies signed an extended contract worth more than $850 milli.
The 2016 deal was valued at $1 billion with a commitment of $265 million in cash, including a $125 million upfront payment and $35 million due in early 201 The agreement also gives Otsuka Pharmaceuticals co-commercialization rights for Akebia's drug in the.
, with the Japanese drugmaker providing $105 million to help cover development costs and up to $765 million in mileston.
In 2017, the companies agreed to extend the deal, giving Otsuka access to Europe, China, Russia and much of the rest of the wor.
Otsuka Holdings agreed to pay an additional $208 million, including an upfront payment of $73 million, $135 million to cover additional development costs, and $657 million for potential mileston.
Combined with Akebia's $350 million Asia-focused deal with Mitsubishi Tanabe in 2015, vadadustat could potentially be worth more than $2 billi.
And now, all is go.
After Otsuka sent Akebia a written notice to terminate the partnership on May 12, the two companies announced the termination of the partnership on Frid.
Akebia said in a filing with the.
Securities and Exchange Commission on Friday that the termination agreement will take effect a year lat.
Poor trial data, FDA issued CRL for safety reasons
"Otsuka and Akebia have been co-developing vadadustat for renal anemia, but in March of this year, Akebia received a Complete Response Letter (CRL) from the.
Food and Drug Administration (FDA)," Otsuka said in a statement Frid.
.
Therefore, Otsuka has decided to terminate the co-development of vadadustat and has notified Akebia to terminate its global license agreeme.
”
The companies said the FDA issued the CRL due to safety concerns, requesting additional trials, noting that the agency's safety concerns focus on the drug's "non-inferiority of MACE in the non-dialysis patient population, which was determined by dialysis patien.
Increased risk of thromboembolic events due to vascular access thrombosis, as well as risk of drug-induced liver inju.
"
"
Akebia CEO John Butler expressed disappointment with CRL, even as some analysts predicted the drug would be approv.
Akebia said at the time, "The CRL states that Akebia can explore a potentially beneficial approach to benefit-risk assessment through new clinical tria.
Akebiawill discuss the details of the CRL with its partners and request a meeting with the F.
"
Shares of Akebia have also fallen sharply in the past two mont.
At the end of March, the company's shares were trading around $44, but on the day the CRL was announced, the company's shares plunged 66% to $8 Shares of Akebia (AKBA) were hovering around 40 cents a share as of Monday morni.
Akebia also said in its current statement (Material Events) filed last Friday that Otsuka terminated the deal because of "the company's alleged breach of the Otsuka.
Agreement," which could force the deal to close as early as June 1 Akebia further added that it disagreed with this assertion and planned to refute the allegations of a "material breac.
Akebia also added in its current statement (Material Events) that it received a notification from Nasdaq that it had until N.
8 to recover its share price to at least $ Otherwise, it will be delist.
Mode three
Mode threeSelect product cooperation, join popular track
Select product cooperation, join popular track It is common for small biotech companies with unique technology platforms to partner with large biopharmaceutical compani.
However, the reason why small biotech companies can attract large pharmaceutical companies mainly depends on their products, and unique products can be favored by large pharmaceutical compani.
AbbVie joins the Treg race to compete with other big pharma companies, and while the field is already crowded, it's clear that the value of hot targets is still not to be underestimat.
What product did AbbVie choose?
On May 16, 2022, AbbVie and Cugene jointly announced a worldwide exclusive license option agreement for CUG25 In a collaboration agreement announced Monday morning, AbbVie said it will work with Cugene to advance a single Treg program targeting IL-2
AbbVie made an upfront payment of $45 million for the partnership and will pay undisclosed milestone and royalty amoun.
Cugene is a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines that harness specific immune cells to treat autoimmune diseases and canc.
AbbVie also received an exclusive license to certain IL-2-targeting Treg programs, including CUG252 in Monday's de.
CUG252 is a potentially best-in-class Treg-selective IL-2 mutant protein for the treatment of autoimmune and inflammatory diseas.
CUG252 is an engineered IL-2 mutein designed to selectively activate and expand immunosuppressive Treg cells while reducing unwanted IL-2 activity on other IL-2 receptor expressing cells, the researchers hope Using Treg cells to treat autoimmune diseas.
CUG252 is Cugene's only clinical program to da.
"Today's agreement highlights CUG252, a unique precision-engineered platform that has resulted in multiple product candidates including CUG252," Cugene CEO Luke Li said in a statement Mond.
The increasingly crowded Treg track
Treg cells are a subset of CD4 T cells with significant immunosuppressive effects, which can inhibit the immune response of other cells and play an important role in maintaining the body's immune balance and preventing autoimmune diseases and transplant rejecti.
Treg therapy is mostly used to treat autoimmune diseases and organ transplant rejection, and these indications are also the fastest in clinical resear.
Treg has also become a promising target in tumor immunotherapy due to its important role in tumor immuni.
AbbVie joins the Treg race against other big pharma, Merck, Takeda, Amgen, Eli Lilly, Sangamo, and a slew of up-and-coming biotec.
investing in this fie.
The space has grown rapidly over the past 18 months or so, especially following Merck's $85 billion acquisition of Pandion in February 202
Trust Securities analyst Robyn Karnauskas pointed out that it is too early to identify a winner or front runner in this big pharma ra.
AbbVie's partnership with Cugene is another validation of this partnership model, while further cementing AbbVie's dominance in the field of immunothera.
The deal would also give Sangamo a competitive advantage, Karnauskas said, the only company currently using an "engineered CAR-Treg cell thera.
"
For Cugene, meanwhile, the deal could give the little-known biotech company a big na.
Mode four
Mode fourPrivate Equity Enters the Market, Opens the Acquisition Model
Private Equity Enters the Market, Opens the Acquisition Model The new crown epidemic has pushed the biotech industry to its peak, but with the end of the new crown epidemic "feast", is this explosive prosperity still sustainable?.
stocks have been up and down recently, and the biopharmaceutical board can be described as a thriving market leading the market, which has also attracted many investo.
Globally renowned private equity firms like Apollo are also entering the biotech spa.
What others see as a bear market is an investment opportunity for private equity companies to hunt for bargai.
I believe that excellent companies and products can always stand firm in the mark.
Apollo enters the market, which will bring 1 billion euros of transactions
Private equity is making a big move into biote.
The amount of money Antoine Papiernik and Sofinnova Partners can put into biotech has grown significant.
Apollo Global Management, a private equity firm with a market value of $32 billion, has moved to acquire minority stakes in life sciences companies, giving its funds €1 billion in capital under management,it is understoo.
Paris-based Sofinnova — not to be confused with California-based Sofinnova Investments — can also use the “Apollo Platfo.
” Here's an interesting reference to developing a "future strategy",.
selecting new products while increasing investment in biotech innovati.
"This strategic partnership will allow Sofinnova to double down on what it does best: supporting innovation and building the company through long-term relationships with forward-thinking entrepreneurs," noted Papiern.
It's also a big step forward for Apollo, which has so far invested $5 billion in healthca.
"Having Sofinnova's expertise to help us work better is really powerful," Apollo co-president Scott Kleinman told Bloombe.
Shrinking life sciences stocks spurred interest in private equity
That's a sizable financial boost for Sofinnova, which before the deal reported 5 billion euros under manageme.
There is no sign that the public market for biotech is shrinking in the wake of the pandemic-fueled bo.
Quite the contrary, dozens of biotech companies are showing desperation that only fuels interest from private equity firms like Apollo, which is run by billionaire Marc Row.
Before Apollo entered the biotech space, Carlyle had decided to acquire Abingworth and bring in its own te.
Carlyle is excited about the new funding opportunities available to Abingworth and its late-stage development te.
EQT acquired Life Science Partners last fa.
Blackstone bought Clarus on a spree in 201
Sofinnova is a well-known company in Europe, but far from the large.
Analysing the data last fall, Chris Dokomajilar concluded that Sofinnova was fifth on the list, well behind top companies like Janus Henderson and H.
Now that Apollo is on board, the list will likely continue to expa.
Retrieved from https://endp.
com/private-equity-makes-another-big-move-into-biotech-as-apollo-executes-e1b-play-while-life-sci-stocks-shrivel/
Summarize
Under the bear market, both multinational pharmaceutical companies and domestic pharmaceutical companies are affect.
There are various reasons that lead to fluctuations in the stock prices of pharmaceutical companies, such as layoffs and projects due to lack of funds, the suspension of clinical trials due to the epidemic, and the lack of experimental da.
The failure of product lines caused by the best product lines, the high R&D costs caused by too many product lines, and the uncompetitiveness of products due to too much homogenei.
The research and development of new drugs is a high-investment, long-term and high-risk matt.
At the same time, the innovation of biomedicine relies on strong basic research
It can be said that the real innovation is a life-and-death experien.
In the face of the high risk of life and death, many people will choose to give up, but there is a clinical need and a market dema.
This is an opportunity and an opportunity for high retur.
In the long run, R&D and innovation capabilities are still the core of the competitiveness of biotech companies and the focus of investors' attention
Whether it is a large multinational pharmaceutical company or a domestic pharmaceutical company, innovation is the only way for pharmaceutical companies to break throu.
In fact, behind the rapid decline in the enthusiasm of the capital market is the concentrated outbreak of problems such as the concentration of innovative drug targets, product homogeneity, and insufficient commercialization val.
The survival mode of the above four biotech companies is only a microcosm of the development and progress of pharmaceutical compani.
The survival of pharmaceutical companies will be a normal state in the futu.
For a pharmaceutical company, R&D is undoubtedly the key to life and dea.
No matter which survival mode is chosen, the ultimate goal is to make the research and development of products sustainable and ultimately bring considerable benefits to pharmaceutical compani.
In the bear market of "real gold is not afraid of fire", I believe that good products can still attract capital and lead the mark.
References
References [1] https://endp.
com/ahead-of-new-barda-deal-emergent-acquires-smallpox-drug/
com/ahead-of-new-barda-deal-emergent-acquires-smallpox-drug/
[2] https://endp.
com/otsuka-calls-off-multi-billion-dollar-ckd-licensing-deal-with-akebia-in-aftermath-of-crl/
com/otsuka-calls-off-multi-billion-dollar-ckd-licensing-deal-with-akebia-in-aftermath-of-crl/
[3] https://endp.
com/treg-space-continues-to-heat-up-as-abbvie-puts-up-almost-50m-upfront-to-partner-with-little-known-biotech/
com/treg-space-continues-to-heat-up-as-abbvie-puts-up-almost-50m-upfront-to-partner-with-little-known-biotech/
[4] https://endp.
com/private-equity-makes-another-big-move-into-biotech-as-apollo-executes-e1b-play-while-life-sci-stocks-shrivel/
com/private-equity-makes-another-big-move-into-biotech-as-apollo-executes-e1b-play-while-life-sci-stocks-shrivel/